黄芪对慢性阻塞性肺疾病疗效的Meta分析

Efficacy of Astragalus on Chronic Obstructive Pulmonary Disease:A Meta-analysis

目的评价黄芪对慢性阻塞性肺疾病的疗效。方法计算机检索PubMed、中国学术期刊全文数据库、中国生物医学文献数据库、万方资源数据库、重庆维普网和中国重要会议论文全文数据库并手工检索相关期刊,全面收集黄芪治疗慢性阻塞性肺疾病的随机或半随机对照研究,对选入文献进行质量评价,并提取有效数据进行Meta分析。结果最终纳入6篇文献,均为中文文献,包括437例患者(试验组220例,对照组217例),各组间具有基线可比性。系统评价结果显示:黄芪能改善慢性阻塞性肺疾病患者肺功能(1 s用力呼气容积/用力肺活量,FEV1/FVC)〔WMD=4.32,95%CI(2.10,6.55),P=0.0001〕,但临床疗效无明显改善〔RR=1.18,95%CI(0.95,1.46),P=0.14〕。结论 Meta分析提示,黄芪能改善慢性阻塞性肺疾病患者的肺功能,未能改善临床疗效。因此,还需要更多前瞻性、大规模的临床随机对照研究加以验证。

Objective To assess the efficacy of Astragalus on chronic obstructive pulmonary disease （COPD） . Methotis The randomized or semi -randomized controlled studies involving treatment of COPD with Astragalus were searched and identified from PubMed, China Academic Journals Full -text database, Chinese Biomedical Literature Database, WanFang Resource Database, Chongqing VIP and Chinese Journal Full - text database. The qualities of literature were evaluated and then the valid data were extracted for Meta - analysis. Results Eventually 6 articles, all in Chinese, including 437 cases of patients （220 in experimental group and 217 in control group） were included, with baseline comparability between groups. Systematic review showed that Astragalus could help COPD patients to improve their lung functions （FEV1/FVC） [ WMD = 4. 32, 95 % CI （ 2. 10, 6. 55 ） , P = 0. 0001 ] , however, there was no significant improvement in clinical efficacy comparing to the control group [RR = 1.18, 95% C1 （0. 95, 1.46）, P =0. 141. Conclusion The Metaanalysis shows that astragalus could improve lung function in COPD patients, but it failed to improve the clinical efficacy. Therefore it needs more forward -looking, large -scale randomized controlled clinical trials to verify.